Latest news with #SAGETherapeutics
Business Insider
16 hours ago
- Business
- Business Insider
J.P. Morgan Remains a Hold on SAGE Therapeutics (SAGE)
In a report released on June 20, Anupam Rama from J.P. Morgan maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $8.50. The company's shares closed last Friday at $9.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Rama covers the Healthcare sector, focusing on stocks such as Neurocrine, Sarepta Therapeutics, and Vera Therapeutics. According to TipRanks, Rama has an average return of -6.9% and a 37.70% success rate on recommended stocks. SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $9.04, which is a -2.80% downside from current levels. In a report released on June 20, Robert W. Baird also maintained a Hold rating on the stock with a $9.00 price target. The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.52M.
Business Insider
6 days ago
- Business
- Business Insider
TD Cowen Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
TD Cowen analyst Ritu Baral maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $8.50. The company's shares closed today at $9.07. Confident Investing Starts Here: Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Alnylam Pharma, and Neurogene. According to TipRanks, Baral has an average return of 7.3% and a 46.40% success rate on recommended stocks. SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $8.75, representing a -3.53% downside. In a report released today, Wedbush also maintained a Hold rating on the stock with a $8.50 price target. Based on SAGE Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $14.06 million and a GAAP net loss of $62.21 million. In comparison, last year the company earned a revenue of $7.9 million and had a GAAP net loss of $108.48 million
